Account
Insider Insights
23.02.2024
New Committee Paves the Way for Biosimilar Substit...

ANSM establishes a Temporary Scientific Committee to promote biosimilar substitution, enhancing pati...

Read more
Insider Insights
16.02.2024
Biosimilar Switching in Germany from March 15, 202...

New biosimilar switching regulations prioritise cost-effective options and discount agreements, imp...

Read more
Case Study
26.04.2023
Developing a pharmacy submission pack

Our client wanted to broaden access and funding for their reproduction biosimilar in the UK. However...

Read more
Case Study
26.04.2023
Biosimilar country pricing and market access

Our client wanted to gain a better understanding of current and forthcoming policy measures affectin...

Read more
Case Study
26.04.2023
Partnered with a biosimilar company

Development and submission of payer communication materials and pricing and reimbursement dossiers f...

Read more
News
17.02.2023
PMA Insights: Week 7

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
08.02.2023
First Adalimumab Biosimilar Launch in the USA

The first adalimumab (branded Humira) biosimilar, Amjevita, has been launched in the US by pharmaceu...

Read more
Case Study
01.01.2023
Providing support in peer reviewed publication

Our client asked Remap Consulting to support them in the development of a peer-reviewed publication ...

Read more
Case Study
01.01.2023
Development of EU country level biosimilar pricing

Development of local market access plans that could be used by EU affiliates, who had not previously...

Read more
Articles
25.10.2022
How is International Reference Pricing used within...

We discuss the advantages and disadvantages of using international reference pricing for consistent ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.